MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma

Journal of Clinical Pathology

Volumn 67, Issue 8, 2014, Pages 697-701

  Augello, Claudia ^a   Gianelli, Umberto ^a   Savi, Federica ^b   Moro, Alessia ^b   Bonoldi, Emanuela ^c   Gambacorta, Marcello ^d   Vaira, Valentina ^e   Baldini, Luca ^a   Bosari, Silvano ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c A MANZONI HOSPITAL   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS; LYMPHOMA; VIRUS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPACIVIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905095831     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202352     Document Type: Article

References (25)

1. Peveling-Oberhag J, Arcaini L, Hansmann ML, et al. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169-77.
2. De Re V, Caggiari L, Garziera M, et al . Molecular signature in HCV-positive lymphomas. Clin Dev Immunol 2012;2012:623465. http://dx.doi.org/10. 1155/2012/623465
3. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011;117:1792-8.
4. Alizadeh AA, Eisen MB, Davis RE, et al . Distinct types of diffuse large B-cell lymphoma identified by gene expression pro filing. Nature 2000;403:503-11. (Pubitemid 30082188)
5. Bea S, Zettl A, Wright G, et al. Lymphoma/Leukemia Molecular Profiling Project. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-90. (Pubitemid 41565917)
6. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007;60:1378-83. (Pubitemid 350247254)
7. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus - positive patients in LNH93 and LNH98 groupe d' etude des lymphomes de l'adulte programs. J Clin Oncol 2006;24:953-60. (Pubitemid 46638850)
8. Augello C, Vaira V, Caruso L, et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 2012;32:772-82.
9. Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. Annu Rev Microbiol 2010;64:123-41.
10. Lung RW, Tong JH, To KF. Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy. Int J Mol Sci 2013;14:17378-409.
11. Jardin F, Figeac M. MicroRNAs in lymphoma, from diagnosis to targeted therapy. Curr Opin Oncol 2013;25:480-6.
12. Mazan-Mamczarz K, Gartenhaus RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk Res 2013;37:1420-8.
13. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.
14. Vaira V, Faversani A, Dohi T, et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 2012;31:27-38.
15. Vergoulis T, Vlachos IS, Alexiou P, et al. Tarbase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucl Acids Res 2012;40:D222-9.
16. Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012;26:1654-62.
17. Mazan-Mamczarz K, Gartenhaus RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk Res 2013;37:1420-8.
18. Jopling C. Liver-specific microR-122: Biogenesis and function. RNA Biol 2012;9:137-42.
19. Kawauchi K, Ogasawara T, Yasuyama M, et al. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 2009;9:550-9.
20. Beà S, Colomo L, López-Guillermo A, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004;22:3498-506. (Pubitemid 41103656)
21. Wang W, Zhao LJ, Tan YX, et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012;33:1113-20.
22. Zhao X, Yang L, Hu J, et al. miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010;34:1078-82.
23. Golubovskaya VM, Sumbler B, Ho B, et al . MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem 2014;14:18-28.
24. Tserel L, Runnel T, Kisand K, et al. MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J Biol Chem 2011;286:26487-95.
25. Liu G, Friggeri A, Yang Y, et al. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A 2009;106:15819-24.